Value-Based Contracting Messaging for Specialty Pharmacy Brands

Value-Based Contracting Messaging for Specialty Pharmacy Brands ⟦c1⟧

Specialty pharmacy brands face a different VBC conversation

Specialty pharmacy brands sit at a negotiating table that looks nothing like the one general pharma occupies, and the numbers explain why⟦c3⟧⟦c4⟧. Specialty drugs climbed from roughly a quarter of total US Rx dispensing revenue in 2013 to nearly 40% by 2023, a shift that changed the structure of the market as well as its size⟦c3⟧. Total specialty Rx revenue hit approximately $235 billion that year, accounting for 54% of all US drug expenditures, and that concentration of dollars means payers, prescribers, and patients each feel the weight of these drugs in entirely different ways⟦c4⟧.

The pipeline keeps the pressure constant. Over 80% of the 55 novel FDA approvals in 2023 were specialty drugs, so a brand cannot treat a value-based contract as a one-time negotiation to get through and then forget⟦c5⟧. It is a recurring conversation that resets with every new indication, every new competitor, every new data readout. Half of specialty drugs are administered under the medical benefit rather than the pharmacy benefit, which changes who actually controls the purse strings and who the brand needs to convince first⟦c6⟧. That split-benefit reality alone makes the contracting environment for specialty therapies structurally different from a retail branded drug moving through a standard formulary process.

Add to that the absence of precedent. The gross-to-net bubble, the gap between list price and what manufacturers actually collect after rebates and discounts, reached $187 billion in 2020, but high-cost orphan and rare disease therapies have largely sat outside that bubble⟦c7⟧. Fewer deals have been done in this exact price range, for this exact patient population, under this exact benefit structure. Brands negotiating VBCs for gene therapies or ultra-rare disease treatments do not inherit a deep playbook the way a manufacturer of a diabetes drug might ⟦c53⟧.

None of this would matter as much if "value" meant the same thing to everyone in the room. Value does not mean the same thing to everyone in the room. Payers define value as total cost of care across a population. Prescribers define it as a clinical outcome for the one patient sitting in front of them. Patients define it as access, affordability, and relief from a specific burden. A single VBC message built to satisfy all three at once satisfies none of them⟦c8⟧. The rest of this piece works through what each audience actually needs to hear, and why collapsing those needs into one script is the fastest way to lose credibility with everyone.

Payer needs before signing a VBC

Payers are not resisting specialty drugs because they doubt the science. They are resisting because they have been asked to pay $200,000 to $2 million per treatment course with limited proof that the therapy outperforms a cheaper alternative, and they are tired of absorbing the cost of failure⟦c9⟧. The real issue on the payer side of the table is risk transfer, not efficacy. A brand that walks in prepared to argue clinical superiority alone is answering a question the payer stopped asking a while ago.

Operational readiness matters just as much as the drug's performance data. In one payer survey, 64% of payers named insufficient data infrastructure as a deal-killer ⟦c10⟧. A brand's message has to speak to whether the payer can even execute the contract it is being asked to sign, and the drug working is not enough on its own⟦c10⟧. Proof-point selection, in other words, is itself an act of negotiation. Brands that show up with a pre-defined, payer-legible metric, one that can be adjudicated from claims data or EHR records the payer already holds, compress the time it takes to reach a signed deal⟦c12⟧.

Payer messaging has to demonstrate a short list of things, and none of them are optional. It needs a clearly defined short-term outcome the payer can measure without building new infrastructure⟦c12⟧. It needs a risk-sharing structure, whether that is a rebate, a refund, an installment model, or a warranty, explained in financial terms rather than clinical ones⟦c9⟧. It needs total cost-of-care framing: hospitalizations avoided and downstream procedures reduced, and it needs this framing instead of just the sticker price of the drug itself. It needs regulatory fluency, particularly around the CMS multiple best-price rule effective January 2026, which now lets manufacturers report multiple best prices for VBC arrangements and requires a working understanding of Medicaid safe-harbor mechanics⟦c13⟧. And it needs a data-sharing plan that spells out how outcomes get tracked, who owns attribution, and what happens when the data comes back incomplete.

Payers increasingly measure new proposals against a specific federal template. And the IRA complicates the picture further: the Maximum Fair Price takes effect in January 2026 for ten Part D drugs, including Eliquis, Xarelto, Entresto, Enbrel, and Stelara, and for those, the traditional logic of outcomes-based rebates gets squeezed⟦c16⟧. Brand messaging needs to say whether a given therapy sits inside or outside the IRA negotiation universe, because the answer changes what kind of deal is even possible ⟦c16⟧.

The vocabulary matters, too. Payers respond to terms like guaranteed performance, outcomes-linked rebate trigger, adjudicable metric, total cost offset, and risk corridor, language that converts clinical value into actuarial and budget-impact terms. Leading with clinical trial p-values, patient testimonials, or an unquantified claim about improved quality of life signals, to a payer, that the brand has not done its homework. 84% of negotiations stall because parties cannot agree on a valid, measurable outcome (per IntuitionLabs analysis), and proof-point selection is itself a negotiating act, with brands that arrive with pre-defined, payer-legible metrics compressing time-to-deal ⟦c11⟧. The CMS CGT Access Model, with 33 states plus DC and Puerto Rico participating and representing 84% of Medicaid beneficiaries with sickle cell disease, now serves as a template payers reference, as payer audiences increasingly expect manufacturers to come to the table with a CMS-style structured outcomes framework ⟦c14⟧. Casgevy's list price of $2.2 million and Lyfgenia's list price of $3.1 million are now part of every payer's mental model for what "high-cost gene therapy" means; specialty brands below that ceiling still need to address the reference anxiety those prices created ⟦c15⟧.

The payer's proof point becomes real-world evidence, not just the manufacturer's

Real-world evidence is what makes a value-based contract adjudicable in the first place⟦c17⟧. Without it, contracts fall back on claims-based proxies that satisfy neither side, because a proxy metric is always an approximation of the outcome anyone actually cares about. RWE closes that gap, but only if both parties trust the methodology behind it, and that trust has become easier to establish because of recent standard-setting work.

Brands that align their RWE methodology to the payer-focused RWE standards published by AMCP Research Institute, IQVIA, payers, pharmaceutical companies, and others in JMCP in September 2025 reduce the negotiation overhead for payer counterparties ⟦c18⟧. Separately, the 2025 ICER Special Assessment on cell and gene therapy financing recommended standardized data templates for outcomes contracts, and several payers have already adopted those templates as a starting point for their own negotiations⟦c19⟧. Citing alignment with either of these frameworks functions as a credibility shortcut; it tells the payer the brand is speaking a language the payer's own analysts already use.

The regulatory bar has also moved. That lowers what brands need to produce, but payers still need the shift explained to them directly, since the change is easy to miss and easy to misread as a lowering of evidentiary standards rather than a change in submission mechanics.

Brands also need to be honest about where the data gaps sit. Regional health plans, in payer surveys, often find that only a fraction of relevant patients have lab values available inside their in-network EHR systems, with the rest tested somewhere outside the network entirely⟦c21⟧. Hospital data rarely links cleanly with outpatient pharmacy data, and specialty clinic registries often cannot connect to payer claims systems. A brand that shows up with a proposed reconciliation method for these gaps, rather than a vague promise that "the data will be there," earns more trust than one that pretends the gap does not exist.

Specialty pharmacies themselves function as RWE nodes in this system ⟦c18⟧. They interact with patients more often than individual prescribers do. They can collect patient-reported outcomes that neither payer nor prescriber has direct access to⟦c22⟧. Pairing that touchpoint frequency with AI-driven analytics platforms, which are letting industry leaders scale outcomes-based contracts past the pilot stage, gives a brand something concrete to point to beyond a single published study⟦c23⟧. The posture that lands best with payers frames RWE not as the manufacturer's defense of its own drug, but as shared infrastructure the payer benefits from directly, a way for the payer to watch its own population's response to therapy in something close to real time⟦c24⟧.

Prescriber needs in a VBC conversation, distinct from the payer's conversation translated

Prescribers are no longer bystanders in value-based contracting. HCP participation in VBC models rose 25% from 2023 to 2024 ⟦c25⟧. Physicians are increasingly named parties inside these arrangements, not passive recipients of a deal struck somewhere above them⟦c25⟧. A national survey found that 72% of stakeholders believe VBC will become the dominant reimbursement model within five years, so prescribers who remain skeptical today are practicing inside a system that is moving past that skepticism regardless⟦c26⟧.

The prescriber's definition of value has almost nothing to do with the payer's. A prescriber wants to know whether the drug works for the specific patient in the exam room, with that patient's comorbidities and life circumstances, rather than whether it worked for the cohort enrolled in a phase 3 trial⟦c27⟧. Translating a VBC's outcome metric into that language matters enormously ⟦c5⟧. A payer-facing term like an "HbA1c reduction trigger" needs to become, for the prescriber, a plain statement of what the patient needs to achieve and why this particular therapy makes that achievable⟦c28⟧.

Attribution anxiety shapes almost every prescriber conversation about VBCs, whether it gets said out loud or not ⟦c53⟧. Prescribers worry that if a patient does not adhere to a regimen, their own performance numbers under the contract take the hit, so messaging has to say clearly who bears the adherence risk and how the contract structure accounts for patient behavior that is genuinely outside the prescriber's control⟦c29⟧. Prescribers also need to see, not just hear about, the wraparound support built into the contract: medication therapy management, adherence programs, patient-reported outcome collection⟦c30⟧. A rebate trigger by itself tells a prescriber nothing about whether their patient will actually get the support needed to hit it.

This matters most for the population that specialty pharmacy value-based contracting efforts are actually built around: the polychronic, polypharmacy patients who make up roughly 20% of the population but account for about 80% of healthcare spending⟦c31⟧.

The language that works here is deliberately different from payer language. Prescribers respond to phrases like "outcome endpoint your patient can reach," "adherence support built in," and "you won't be penalized for complexity." Leading a prescriber conversation with rebate mechanics, Medicaid best-price rules, or financial risk structures reads as a payer concern, and it signals that the brand doesn't understand what the prescriber is accountable for⟦c32⟧. The XiFin 2025 Pharmacy Transformation Outlook Survey, drawing on more than 350 respondents, found pharmacists increasingly stepping into integrated patient management roles ⟦c33⟧. Prescriber-facing messaging should treat the pharmacist as a care-team partner inside the VBC rather than a distribution channel the drug simply passes through⟦c33⟧.

The specialty pharmacy's position as a credibility asset in prescriber conversations

The specialty pharmacy sees the patient more often than the prescriber does, which opens up a category of evidence, patient-reported outcomes collected at scale, that the prescriber cannot generate alone⟦c34⟧. That frequency of contact sits at the center of the VBC story ⟦c5⟧. It is the mechanism that makes certain contract structures possible.

Shields Health Solutions, working with health system partners, found that health system specialty pharmacy infrastructure had a measurable bearing on VBC contract performance, with improvements of up to $1,200 in per-member outcomes value⟦c35⟧. That number matters because it turns an abstract claim, "specialty pharmacy integration improves outcomes," into something closer to a line item. Clinical pharmacists bring pharmacologic knowledge that helps mitigate side effects, a real contributor to adherence, and they conduct medication reconciliation for exactly the polychronic, polypharmacy patients who are hardest to build a contract around⟦c36⟧.

There is also a neutrality argument here that does not exist anywhere else in the chain. Specialty pharmacies are patient-focused and see things about a patient's actual living conditions and medication behavior that manufacturers, prescribers, and payers simply do not have visibility into⟦c37⟧. That neutrality becomes a messaging asset in prescriber conversations specifically, because a prescriber who is wary of a manufacturer's motives will often extend more trust to a pharmacist relationship built on daily contact rather than a sales cycle.

For brand messaging, this means naming names. A prescriber-facing argument gets stronger the moment a brand can identify the specialty pharmacy partner involved and describe, concretely, the adherence and outcomes-tracking support it provides. Abstract talk of "wraparound support" carries far less weight than a named program with documented touchpoints a prescriber can actually picture. Well-structured VBCs build adherence requirements directly into the contract, translating into real care management support for the patient, and prescribers need to hear, explicitly, that adherence is the brand's problem to solve, not something added to their own workload ⟦c53⟧.

What patients understand about value-based contracting (and what the brand must translate for them)

Patients do not perceive a value-based contract as a contract. Nearly 30% of Americans skip prescribed medications because of high drug prices, a Kaiser Family Foundation finding showing that patient-defined value starts with a much blunter question than payers or prescribers ask: can this be afforded, before it ever gets to does it work⟦c38⟧. Prescription abandonment tracks that reality closely. On average 9% of prescriptions go unfilled, but that number drops to 5% when the prescription is free and rises to 60% when the cost exceeds $500, and that spike at high cost-share is the most visible failure mode of any specialty drug VBC, the point where the whole contract can quietly fall apart before the drug ever reaches the patient⟦c39⟧.

Patients are not stakeholders in a VBC the way payers and prescribers are, they are the unit of measurement, and the brand's patient-facing message must reflect that distinction⟦c40⟧.

What patients actually need translated is narrow and specific. An outcomes-based contract needs to become access language, telling patients that if the therapy does not work, they will not be stuck absorbing the full cost, a warranty framing that lands far better than any explanation of rebate mechanics⟦c41⟧. Continuity fear needs direct acknowledgment too. Patients who change jobs or insurance mid-therapy risk losing access under traditional coverage structures, so messaging should address portability wherever the contract actually allows it⟦c41⟧. Adherence requirements need plain explanation: if a VBC's performance guarantee depends on documented adherence, patients need to understand what they are being asked to do and why it protects them, not punish them⟦c42⟧. And outcomes tracking needs to be framed as personalized care rather than surveillance, because collecting patient-reported data will feel invasive the moment it is not explained as something done for the patient's benefit.

There is funding behind this work, too. The CGT Access Model includes optional federal support of up to $9.55 million per participating state for implementation, outreach, and data tracking ⟦c43⟧. Patient navigation and outreach are a fundable, built-in part of the VBC architecture rather than an extra a brand bolts on afterward⟦c43⟧. Language that resonates with patients stays concrete and personal: guaranteed access, if it doesn't work you don't pay the full price, your pharmacist checks in with you, your coverage follows your care. Explaining rebate triggers, best-price rules, or outcomes thresholds in patient materials does the opposite of building trust, because complexity without personal relevance reads as evasion⟦c44⟧.

The regulatory and policy shifts that change what brands are allowed to say (and to whom)

Regulatory hurdles restrict communications between payers and manufacturers, and any brand building a messaging architecture across audiences has to know which conversations are governed by which rules before a single sentence gets written⟦c45⟧. Getting this wrong is not a stylistic misstep. It can be a compliance one.

The CMS final rule effective January 2026 codifies a broad definition of value-based purchasing and allows manufacturers to report multiple best prices when offering VBP arrangements to states, and this is the regulatory foundation that makes payer-facing VBC messaging legally operable in the first place⟦c46⟧. HHS-OIG issued advisory opinions in 2024 and 2025 addressing various Anti-Kickback Statute questions tied to cell and gene therapies, covering things like travel support and patient assistance programs, with a mixed record of favorable and unfavorable outcomes; none of them specifically confirmed that outcomes-based arrangements under the CGT Access Model fall outside AKS scrutiny entirely, but the opinions have still reduced legal uncertainty across one of the most active VBC categories in the market⟦c47⟧. Pfizer's use of best-price reporting flexibility for Beqvez, its hemophilia B gene therapy, gives brands a named, working precedent to point to when explaining the structure to payer counterparts⟦c48⟧.

The IRA Medicare Drug Price Negotiation creates a bifurcated landscape, and messaging has to acknowledge which one a given therapy is in⟦c49⟧. For the ten Part D drugs facing Maximum Fair Price starting January 2026, negotiated prices already reflect discounts of up to 79% off list, leaving little room left for additional performance-contingent rebates layered on top⟦c50⟧. For newer, non-negotiated specialty therapies and cell and gene therapies, manufacturers are increasingly reserving their VBC offers, because that is where genuine room to structure meaningful risk-sharing still exists⟦c51⟧.

None of this moves quickly, and brands should stop expecting it to. As AMCP's December 2023 lexicon put it, value-based contracts often require significant time to reach final negotiation and implementation, and disconnect, misalignment, and the lack of a shared framework for value-based purchasing agreements have made those delays worse⟦c52⟧. A brand that maps its language to what each audience at the table actually needs to hear, payer, prescriber, and patient, will not eliminate that timeline. But it will stop adding its own confusion to a process that already has plenty.